DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

Frontiers in Cardiovascular Medicine

JULY 8, 2024

BackgroundHuman pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) show tremendous promise for cardiac regeneration following myocardial infarction (MI), but their transplantation gives rise to transient ventricular tachycardia (VT) in large-animal MI models, representing a major hurdle to translation.

Pacemaker 52

Pacemaker CMS Arrhythmia Transplant 52

DAIC

DECEMBER 8, 2023

a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company's IDE pivotal trial. These patients have very poor outcomes in terms of death and rehospitalization and therefore new therapy options are critically needed," stated Dr. Chehab.

Technology 113

Technology Heart Failure Heart Transplant Transplant 113